Fasting Insulin and HOMA-IR: The Tests Nobody Orders

The useful facts first, the caveats second, and the myth at the end.

What this actually means

Fasting insulin, combined with fasting glucose in the HOMA-IR calculation, estimates insulin resistance before glucose itself rises. That definition matters because the term gets used loosely in supplement marketing, where a real mechanism is routinely stretched into a promise the evidence does not carry.

It can flag a problem years earlier than a standard glucose test.

Why it matters if you are buying a supplement

Almost every purchase decision in this category comes down to one question: is the product addressing the actual cause of the problem you have? Appetite, sleep debt, an energy surplus, insulin resistance and simple measurement error all produce similar-looking frustration, and they need different responses. Getting the cause right is worth more than getting the product right.

It can flag a problem years earlier than a standard glucose test. That is why the sequence on this site is always the same — understand the mechanism, check the dose against the research, then decide whether a product is buying you anything.

Four things worth knowing

• Insulin rises to compensate long before fasting glucose moves.
• HOMA-IR is a research-derived estimate, not a diagnostic standard.
• Reference ranges vary between laboratories.
• It is not routinely ordered in most primary care settings.

What to do about it

1. Ask whether fasting insulin is appropriate if you have risk factors.
2. Interpret results with a clinician rather than online calculators.
3. Track the trend rather than a single value.

None of those cost anything, which is the point. In weight management the interventions with the best evidence — a moderate energy deficit, adequate protein, resistance training, daily walking and protected sleep — are consistently cheaper and less marketed than the ones with the weakest.

One more framing point. Effect sizes in this field are usually small, and small effects are exactly the ones personal impression cannot detect. A written baseline beats a feeling every time, whether you are testing a supplement, a diet change or a new routine.

It is also worth separating what is measurable from what is marketable. The interventions with the strongest evidence here rarely have a product attached, which tells you something about why you hear about them least.

If you take prescription medication, run any new supplement past a pharmacist first. It takes minutes, it is usually free, and a fully printed label makes the answer immediate.

The myth to drop

Myth: normal glucose means normal metabolic health. Insulin can be compensating heavily.

For background reading from sources with nothing to sell, see FTC — health products compliance guidance and Glucomannan weight-loss randomised trial.

Where ExiTide fits

ExiTide is a once-daily capsule providing 442 mg of actives plus 2 billion CFU: riboflavin 25 mg at 1,470% of the Daily Value, mangosteen 100 mg, prickly pear 4:1 100 mg, cinnamon bark 10:1 100 mg, konjac fibre at 90% glucomannan 50 mg, alpha lipoic acid 25 mg, turmeric at 95% curcumin 15 mg, berberine HCl 15 mg, resveratrol at 20% 12 mg, plus Bifidobacterium breve and Akkermansia muciniphila. Every amount is printed, which is rare and genuinely useful.

Read against this topic, the honest placement is as a background nutritional layer rather than a solution. Cinnamon at a 10:1 ratio and riboflavin are delivered at meaningful amounts; berberine sits at about 1% of its researched dose and the glucomannan at roughly 1.5%. It belongs underneath a deficit, protein, training and sleep — not in place of them. The detail is on our full ExiTide review.

Questions readers ask